Legend Biotech announced CEO Ying Huang stepped down without a permanent replacement in place, naming Alan Bash as interim CEO to ensure continuity around Carvykti commercialization. Investors reacted with share volatility, underscoring how leadership changes can amplify uncertainty in late-stage competition and regulatory timelines for CAR T programs.